Radiopharm Theranostics (RADX) SEC Filings

Radiopharm Theranostics Ltd scheduled its online annual general meeting for November 25, 2026. Shareholders will consider the 2026 reports, an advisory, non-binding remuneration report vote, Bruce Goodwin’s election as a director, approval to issue equity securities under the Omnibus Incentive Plan, and a proposed 10% capacity under Listing Rule 7.1A. The directors recommend voting for Mr. Goodwin’s election, with him abstaining, and for the capacity resolution; they made no recommendation on the remuneration report or incentive-plan resolution.

The company says it is not proposing a specific Listing Rule 7.1A issue now; approval would allow further issues for up to 12 months. Those issues would be for cash in an existing quoted class, priced at no less than 75% of VWAP over 15 trading days. An earlier 7.1A issue comprised 350,457,139 shares on August 3, 2026, at $0.015 per share; reported cash consideration received and spent was $5,256,857, used for drug manufacturing, clinical trials and general working capital.

Radiopharm Theranostics Ltd (RADX) received $8,000,000 from Rockford Capital under a funding facility secured against the company’s anticipated FY26 Research and Development Tax Incentive (RDTI). The company said it will use the funds to support its clinical trial pipeline and general working capital.

The facility carries interest at a commercial rate, with repayment timed to follow receipt of the anticipated FY26 RDTI and due by October 26, 2027. Radiopharm may repay it earlier without penalty. The Australian Government program provides eligible companies a refundable tax offset of up to 43.5%.

Radiopharm Theranostics Ltd (RADX) reported four directors’ interest notices recording cancellation of listed options. Following the changes, Bruce Goodwin reported indirect holdings of 2,777,778 shares and 1,666,667 options; Ian Turner’s reported totals were 12,763,070 shares and 23,694,015 options; Paul Hopper’s were 150,499,206 shares and 36,826,185 options; and Riccardo Canevari’s were 26,568,875 shares and 161,745,632 options.

The company issued 140,028,000 unquoted options under its employee incentive scheme on October 19, 2026. They are subject to a restriction on transfer and are not quoted on ASX until the restriction ends. The notice lists 30,887,000 options issued to key management personnel Dimitris Voliotis. The issue fell within Listing Rule 7.2 exception 13, so security holder approval under Listing Rule 7.1 was not required.

Radiopharm Theranostics Ltd (RADX) is identified as the issuer in a Schedule 13G reporting that Regal Partners Funds Management Pty Limited and Regal Partners Limited each list beneficial ownership of 157,139,443 shares, or 3.34% of the class. The reported position includes 145,146,643 Ordinary Shares and 39,976 American Depositary Shares, each representing 300 Ordinary Shares.

The reporting persons list shared voting and dispositive power over 157,139,443 shares, with sole voting and dispositive power of 0. The signature block identifies Alexandra Rose and Kathleen Liu as Company Secretary.

Radiopharm Theranostics Limited completed an End-of-Phase 2 meeting with the U.S. FDA regarding RAD101’s proposed pivotal clinical development program for brain metastases imaging. The company expects the FDA’s official meeting minutes within approximately 30 days; those minutes will provide the formal record of the meeting and the Agency’s feedback. Radiopharm says it is carrying out Phase 3 readiness activities while awaiting that feedback.

Previously reported Phase 2b results showed 93% concordance with MRI across all evaluable lesions, meeting the trial’s primary endpoint. Radiopharm also said Siemens Healthineers will manufacture and distribute 18F-labeled RAD101 doses for the upcoming U.S. Phase 3 registrational trial. RAD101 has FDA Fast Track Designation to distinguish recurrent disease from treatment effect in brain metastases originating from solid tumors.

Radiopharm Theranostics Ltd reported that 24,000,000 RADAN options expired without exercise or conversion on September 30, 2026; the company stated it was not paying consideration for the cessation. Director Riccardo Canevari separately reported disposal of 24,000,000 unlisted options expiring September 30, 2026, with an exercise price of $0.06. His direct option holdings after the change were 163,301,188, and his reported share interests were 23,918,875 direct and 2,650,000 indirect.

Radiopharm Theranostics Ltd reported a total comprehensive loss of A$56.33 million for fiscal 2026, with accumulated losses of A$199.66 million as of June 30, 2026. Operating activities used A$52,782,838 in cash, compared with A$36,645,477 in fiscal 2025; financing activities provided A$33,374,878. Cash and cash equivalents were A$4,138,074 as of June 30, 2026.

The clinical-stage radiotherapeutics company has no product candidates approved for commercial sale and no product revenue, and does not expect significant revenue until regulatory approval and sales begin. Management forecasts current cash will fund operations through fiscal 2027, with the forecast dependent on assumptions including access to additional funding. Radiopharm disclosed a material uncertainty that may cast significant doubt on its ability to continue as a going concern; its directors nevertheless prepared the financial statements on a going-concern basis.

Radiopharm established an at-the-market facility with Leerink Partners in December 2025, under which it may offer and sell up to US$9,300,000 of ADSs. The company describes the facility as open-market, with no discount or warrant coverage; each ADS represents 300 ordinary shares.

Radiopharm Theranostics Ltd (RADX) reported its corporate governance framework for the financial year ended June 30, 2026, through an Appendix 4G and Corporate Governance Statement. The board comprises three independent and three non-independent directors; Chair Paul Hopper is non-independent.

At June 30, 2026, the company reported 20 people across its organization: 11 men and nine women. The statement says the Audit and Risk Committee reviewed the risk management framework during the reporting period. The board does not consider an internal audit function appropriate or necessary at this stage in the company’s development.